We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Zika Virus Test Kit Receives American Marketing Approval

By LabMedica International staff writers
Posted on 16 Sep 2019
A blood test designed to confirm diagnosis of Zika virus infection has been granted 510(k) marketing approval that allows it to be sold in the United States.

The InBios International (Seattle, WA, USA) ZIKV Detect 2.0 IgM Capture ELISA Kit is intended for the presumptive detection of Zika virus IgM antibodies in human sera collected from individuals who meet the criteria of the [U.S.] Centers for Disease Control and Prevention for Zika virus clinical infection. More...
These criteria include a history of associated clinical symptoms or travel from a geographic location with active Zika transmission.

The assay kit, which is based in part on technology licensed from Washington University (St. Louis, MO, USA), contains all the necessary reagents and controls to perform the test and obtain results in about four hours.

Performance of the InBios Zika assay was evaluated by testing 807 unique specimens from 353 subjects at endemic sites and 256 subjects at non-endemic sites. In samples from patients collected seven days or later after onset of symptoms, results correctly identified more than 90% of patients confirmed positive for Zika IgM and more than 96% of patients confirmed negative. In addition to identifying Zika-IgM positive patient samples, the assay differentiated individuals with Zika IgM from those infected with other flaviviruses (such as dengue or West Nile virus), which cross-react with Zika antibodies.

Results of the test are intended for use in conjunction with clinical observations, patient history, epidemiological information, and other laboratory evidence to make patient management decisions. Zika IgM levels are variable over the course of the infection and may be detectable near day four, post-onset of symptoms and persist up to approximately 12 weeks following initial infection.

"Pregnant women living in or visiting places where Zika is endemic will want to know if they have been exposed to the virus," said technology co-inventor Dr. Michael S. Diamond, professor of molecular microbiology, pathology, and immunology at Washington University. "This test, along with another that detects viral genetic material at very early stages of infection, will help women and their doctors make informed healthcare decisions."


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.